Ageing, Inflammation and Regenerative Medicine: What the Evidence Supports

Scope of This Review

This page is for readers in their fifties and sixties who have noticed slower recovery, lower energy or reduced sharpness, and who are considering elective regenerative treatment while otherwise well.

Two boundaries shape everything below.

Occupation is not a clinical variable. Age, symptoms, inflammatory markers and measured physical function can define a population that gets studied. A job title cannot. There is no trial of cell therapy in any occupational group, and this page makes no claim that professional stress constitutes a distinct medical condition.

Being well changes the calculus. When there is no illness to offset them, the risks of an elective intravenous procedure carry more weight, not less. The safety section below is therefore longer than it would be on a page about treating an established disease.

What Actually Changes With Age

Inflammaging

Ageing is accompanied by two coupled immune changes: immunosenescence, a decline in protective immune function, and inflammaging, a chronic low-grade systemic inflammatory state. The drivers include cellular senescence and the senescence-associated secretory phenotype, metabolic dysregulation, mitochondrial dysfunction and gut microbiome alterations⁹.

This is not a marketing construct. It is measurable, and it predicts things that matter.

In the PolSenior study, interleukin-6 was measured in 3,496 individuals aged 65 and over, alongside C-reactive protein. Both rose in an age-dependent manner across the whole cohort, and both were good predictors of physical performance, cognitive performance and mortality risk — in the population as a whole and in the subgroup classified as ageing successfully¹.

That last point is the useful one. Elevated inflammatory markers carry prognostic weight even in people who are otherwise doing well.

What that does not establish

Knowing that IL-6 predicts outcomes does not tell you that lowering IL-6 improves them. Prognostic markers and treatment targets are different things, and the step between them requires a trial that measures the outcome itself.

Stem cells and ageing

Regenerative capacity declines with age, and mesenchymal stromal cells are the most-studied candidate for restoring it. Their mechanism is understood to be paracrine — the secretome — rather than engraftment and tissue replacement¹⁰. Glucocorticoids influence MSC cell-fate decisions, a relationship studied principally in the context of metabolic disease¹¹.

Two corrections to common descriptions. MSCs are immune evasive, not immune privileged: allogeneic cells can be given without donor matching, but they are cleared by the recipient and the evasion is conditional¹². And they do not durably engraft — whatever effect they have is exerted before clearance.

What Has Randomised Evidence

For cognitive decline in people aged around 60 to 77, the best evidence belongs to a multidomain lifestyle intervention.

The FINGER trial was a double-blind randomised controlled trial enrolling 1,260 participants aged 60–77 who had an elevated dementia risk score and cognition at, or slightly below, the level expected for their age. Participants were randomised to a two-year multidomain intervention — diet, exercise, cognitive training and vascular risk monitoring — or to a control group receiving general health advice. The primary outcome was change in cognition measured by a comprehensive neuropsychological test battery².

This is the trial to know about if the concern is cognitive sharpness in this age band. It is randomised, it is large, it measured cognition directly, and its components are available to anyone.

Nothing on the regenerative side is comparable. No trial of MSC therapy, exosome therapy, NAD+ infusion or any combination of them has measured cognition, decision-making, sustained attention, energy or occupational performance in healthy adults. That is not a gap this page can fill by citing mechanism papers, because mechanism is not outcome.

The Nearest Cell-Therapy Evidence — and Why It Does Not Transfer

There is randomised, placebo-controlled evidence that MSC therapy improves physical function. It comes from frailty, and it is worth reporting accurately for two reasons: it is genuinely positive, and its population is not this page's.

A Phase I/II randomised, double-blind, placebo-controlled trial gave intravenous umbilical cord-derived MSCs or placebo to patients diagnosed with aging frailty. The primary endpoint — the physical component score of the SF-36 — improved from the first post-treatment visit and was sustained, with greater change than placebo (p = 0.042). Quality-of-life scores on the EQ-VAS improved significantly from two months (p = 0.023) through six months (p = 0.002), and the Timed Up and Go test showed a significant group difference³.

A larger randomised dose-finding trial in 148 ambulatory adults with frailty found six-minute walk distance improved by 63.4 metres (95% CI 17.1–109.6; p = 0.0077) at month 9. At month 6 the difference was 41.3 metres (95% CI −2.4–84.9; p = 0.0635) — favourable but not statistically significant⁴.

Both trials enrolled people who met frailty criteria — measurably reduced physiological reserve across multiple systems, assessed against a defined phenotype. That is a clinical population with an identifiable syndrome.

A person who is well, working, exercising and simply noticing that recovery takes longer than it did at 35 is not that population. The frailty results are the closest real evidence to this question, and they do not answer it. Extending them to healthy adults would be assuming exactly what the trials were designed to test.

Safety: What Applies When You Are Well

The most important asymmetry on this page. When treating an established condition, a known risk is weighed against a known benefit. In elective treatment of a well person, the risk is real and the benefit is unproven — so the risk section carries more weight, not less.

Fever. The largest safety synthesis of MSC therapy across indications found no association with acute infusional toxicity, organ system complications, infection, death or malignancy — and a significant association with transient fever (OR 16.82, 95% CI 5.33–53.10)⁵. Both halves of that finding are the finding.

The intravenous route specifically. Safety data from one cell source do not automatically transfer to another. Tissue factor expression and the instant blood-mediated inflammatory reaction are particular concerns for intravascular delivery, and product characteristics differ substantially between bone marrow, adipose and perinatal sources⁶. Umbilical cord and adipose-derived preparations carry the highest tissue factor expression, and administration route materially affects thrombosis risk⁷.

This matters directly: intravenous infusion of umbilical cord-derived cells is the combination those papers identify as carrying the concern.

Product quality. A 2021 investigation traced infections in 20 patients to a single umbilical cord-derived product marketed as stem cell therapy, with 65% of tested vials contaminated⁸. Manufacturing standard and regulatory oversight are not administrative details.

What is not known. No long-term follow-up exists for healthy adults receiving intravenous cell therapy electively. The safety data above come from patients treated for disease.

Biomarkers Are Not Outcomes

A recurring claim in longevity marketing is that a measurement moved — an epigenetic clock, an inflammatory marker, a metabolic panel.

The most cited example is a small study using four epigenetic age estimators, which reported a mean epigenetic age roughly 1.5 years below baseline after a year of treatment. It is worth understanding precisely what it was: nine men, uncontrolled, given a protocol of growth hormone, DHEA and metformin intended to regenerate the thymus. Its authors describe the result as an increase in predicted lifespan based on an epigenetic age estimator¹³.

That is an honest description by the authors of a genuinely interesting finding — and it is a long way from a demonstrated health outcome. It involved neither stem cells nor NAD+.

The general principle holds regardless of the marker: a biomarker moving is a hypothesis about benefit, not a demonstration of one. Ask what clinical outcome was measured, in how many people, against what comparison.

What Sterling-Certified Partner Clinics Offer

For transparency, separately from the evidence above: Sterling-certified partner clinics in Thailand provide allogeneic umbilical cord-derived MSC preparations under Thai FDA oversight, alongside supporting infusion services and diagnostic panels. Cell counts, session structure, programme length, pricing and adjunct services are commercial and clinical arrangements determined at the clinic. They are not findings from the literature and are not presented here as evidence of effect.

Adjunct offerings — including NAD+ infusion, exosome preparations, NK/NKT cell therapy, ozone therapy and vitamin infusions — have no published clinical evidence supporting their use for age-related decline in healthy adults, and form no part of the evidence base described on this page.

Any treatment plan is a matter for a qualified physician who has examined you.

Questions Worth Asking

Of yourself

1. What specifically has changed — sleep, recovery, endurance, concentration? Some of these have well-established causes worth investigating first
2. Am I looking for a treatment, or for reassurance that decline is reversible? Those lead to different decisions
3. Would I accept the same risk for the same evidence if the treatment were free?

Of any provider

1. What clinical outcome does this treatment improve, in what population, in what trial?
2. Has that outcome been measured in people like me — well, working, no diagnosed condition?
3. What is the cell source and route, and what is the specific risk profile of that combination?
4. What proportion of your clients report no change?
5. What would make you tell me not to do this?

Of your physician

1. Do my inflammatory markers or metabolic panel show anything that warrants attention?
2. Is there a treatable cause for the fatigue — sleep apnoea, thyroid function, anaemia, medication effects?
3. What would you prioritise if I wanted to invest in the next twenty years of health?

Frequently Asked Questions

Does stem cell therapy improve cognitive performance?

No trial has tested it. There is no human evidence that MSC therapy, exosome therapy or NAD+ infusion improves cognition, concentration, decision-making or work performance in healthy adults.

Is there a specific protocol for executives or high performers?

No. There is no clinical evidence base for any occupational group, and occupation does not define a population that can be studied. Age, symptoms, measured function and biomarkers do.

But the frailty trials were positive — doesn't that apply?

They were positive, and they are reported above at full strength. They enrolled people meeting frailty criteria³ ⁴. If you are well and active, you are not that population, and applying their results to you assumes the thing the trials were built to test.

Does it reverse ageing?

Nothing in this literature demonstrates that. Some interventions move biomarkers, including epigenetic age estimators¹³; no trial has shown that a healthy adult who receives cell therapy lives longer, stays healthier, or declines more slowly.

What is the strongest thing I could do for cognitive health in my sixties?

On randomised evidence, a multidomain programme of diet, exercise, cognitive training and vascular risk management — the FINGER intervention, tested over two years in 1,260 people in this exact age band².

Is intravenous cell therapy safe for someone healthy?

The safety data come from patients treated for disease, not from healthy adults, and they are reassuring on serious outcomes while showing a significant fever association⁵. The intravenous route with umbilical cord-derived cells is the specific combination flagged for tissue-factor–related thrombotic concern⁶ ⁷, and unregulated products have caused infections⁸. For a well person, those risks are not offset by treating an illness.

Should inflammatory markers be checked?

Measuring IL-6 and CRP is reasonable and they carry genuine prognostic weight¹. Whether lowering them by any specific means improves outcomes has not been established.